LS-P-MYTHIC

Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

Status:

OPEN TO ACCRUAL

Trial Type:
Breast, Endocrine Neuroendocrine, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Skin, Thoracic, Unknown Primary
Age Group:
Adults
Phase:

I

NCT Number:

NCT04855656

Contact:

Carneiro, Benedito

benedito.carneiro@BrownHealth.org